Non Small-cell Lung Cancer Clinical Trial
Official title:
CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER PATIENTS ASSOCIATED WITH THE CHOROMOSOME 2p (EML4-ALK) INVERSION IN MEXICAN POPULATION.
Because ALK-positive lung cancer constitutes less than 5% of all lung cancers, it is critically important to select those patients who are more likely to have the ALK mutation. Clinical characteristics of patients with mutations in the target gene should also be known, so that the incidence of a given target mutation is established in a specific population. There is not incidence known in Mexican population, but it is believed it is greater.
Lung adenocarcinoma studies. The only inclusion criterion was the availability of tissue for
biomarker studies. To identify ALK rearrangements, fluorescence in situ hybridization (FISH)
studies were performed on 3 to 4 mm thick paraffin sections from NSCLCs. The commercially
labeled Vysis LSI ALK Dual Color (split-apart), break-apart rearrangement probe (Abbott
Molecular, Abbott Park, IL) was used to detect any rearrangement involving the ALK gene. The
probe hybridizes to band 2p23, on either side of the ALK gene breakpoint. Criteria for probe
signal interpretation in at least 200 interphase nuclei were as follow: 1) separated green
and orange signals or single red signals identified cells with rearranged ALK; 2) overlapping
of red and green signals (yellowish) indicated cells in which ALK was not rearranged.
FISH-positive samples for ALK rearrangement were defined as having cells with a clearly
separated pair of probe signals, or with >15% of cells having loss of the 5´(centromeric)
probe. The higher threshold for loss is necessary because parts of probes can be lost during
sectioning.
The aim of our study is to evaluate the utility of IHC with 5A4 and RT-qPCR in the detection
of ALK rearrangements in NSCLC compared with the current method of choice, FISH. Further, we
report on the demographics, and clinicopathologic features of ALK-rearranged NSCLC in a
Latin-American population.
Clinical details of these patients were included in a database. Further results will be
analyzed with the program SPSS17
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01652820 -
Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01402089 -
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
|
Phase 4 | |
Completed |
NCT01257139 -
Trial Involving Subjects Over 70 Years of Age With Non Small-cell Lung Cancer of Stage IV and Comparing a "Classical" Strategy of Treatment Allocation, With an"Optimized" Strategy Allocating the Same Treatments
|
Phase 3 | |
Active, not recruiting |
NCT05462795 -
Liquid Biopsy for Early Non-small Lung Cancer Detection
|
||
No longer available |
NCT04667234 -
Expanded Access of Sotorasib
|